Lv1
80 积分 2023-08-02 加入
Safety Division, Pharmaceutical and Medical safety Bureau, Ministry of Health and Welfare
2天前
已完结
[Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)]
5天前
已完结
Guidelines for the diagnosis and treatment of rosacea in China （2021 edition）
6个月前
已完结
Guideline for diagnosis and treatment of atopic dermatitis in China （2020）
6个月前
已完结
Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume
7个月前
已完结
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial
7个月前
已完结
Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study
7个月前
已完结
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial
7个月前
已完结
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations
8个月前
已完结
皖公网安备34019202002308
